Volume 15

Issue 4

Article 12

2007

Toxicity of Panax genseng - An herbal medicine and dietary
supplement

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Chan, P.-C. and Fu, P.P. (2007) "Toxicity of Panax genseng - An herbal medicine and dietary supplement,"
Journal of Food and Drug Analysis: Vol. 15 : Iss. 4 , Article 12.
Available at: https://doi.org/10.38212/2224-6614.2397

This Review Article is brought to you for free and open access by Journal of Food and Drug Analysis. It has been
accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug
Analysis.

416
Journal of Food and Drug Analysis, Vol. 15, No. 4, 2007, Pages 416-427

藥物食品分析

第十五卷

第四期

Toxicity of Panax Genseng – An Herbal Medicine and
Dietary Supplement
PO-CHUEN CHAN1* AND PETER P. FU2*
1.

National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, U.S.A.
2.
National Center for Toxicological Research, Jefferson, AR 72079, U.S.A.

(This article is not an official guidance or policy statement of National Toxicology Program (NTP) or U.S. Food and Drug Administration (FDA).
No official support or endorsement by the U.S. FDA and NTP is intended or should be inferred.)

ABSTRACT
Ginseng is one of the most popular herbal dietary supplements in the U.S. market, with five to six million persons using it even
before the recent boom in the herbal supplement industry. Ginsana (G115 ginseng), a standardized extract of Panax ginseng (Asian
ginseng, also called Chinese or Korean ginseng) controls half of this market. Numerous reports of adverse effects from products
containing ginseng have been filed with the U.S. Food and Drug Administration (FDA). The literature also documents “ginseng
abuse syndrome” among regular users. The chronic effects of ginseng are not well characterized. Because of its significant human
exposure and little information on toxicity is available, Panax ginseng has been nominated by the U.S. National Institutes of
Health (NIH) to the U.S. National Toxicology Program (NTP) for assessing its carcinogenic potential. In this review, we discuss
the environmental occurrence, purported therapeutic effects, biological effects, and toxicity of ginseng, with focus on Panax
ginseng. To demonstrate how NTP chronic tumorigenicity bioassays are conducted, the tumorigenicity bioassay of Panax ginseng
is detailed described.
Key words: ginseng dietary supplement, NTP, chronic tumorigenicity bioassay

INTRODUCTION
Ginsengs are members of the genus Panax in the
Araliaceae family. Panax ginseng (Asian ginseng, also
called Chinese or Korean ginseng) and Panax quinquefolius (American and Canada ginseng) are the two most
popular species; other ginsengs include Panax japonicus
(Japanese ginseng), Panax notoginseng (Sanqui or Tienqi
ginseng), Panax elegantior (Pearl ginseng), Panax pseudoginseng (Himalayan ginseng), and Panax zingiberensis (ginger ginseng)(1). In this review, only Ginseng from
Panax ginseng and Panax quinquefolius is considered.
Ginseng is a perennial aromatic herbal plant, reaching
maturity after five years; and for medicinal purposes, it is
usually harvested in its sixth year(2,3). White root ginseng
and red root ginseng are the most popular ginseng products. White root ginseng is prepared by drying the peeled
roots in the sun; red root ginseng is the steam-dried roots
without peeling. In general, ginseng roots are graded by
size. Ginseng root with a larger number (size) is more
valuable than that with a smaller number (size)(1).
Because ginseng is expensive, adulteration or substitution with cheaper products occurs (1). For example,
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commercial ginsengs were found to be adulterated with
phenylbutazone and aminopyrine (4). A comprehensive
program was initiated by the American Botanical Council to determine ginseng adulteration(1,5).
The standardized ginseng products are Ginsana
(contains 4% ginsenosides) or G115 for Panax ginseng
C.A. Meyer and CNT-2000 for Panax quinquefolius, with
which the assessment of efficacy and safety standards for
ginseng products can be pursued (6).

CHEMICAL COMPOSITION
There are many chemical components in ginseng
root, including triterpene saponins, polyacetylenes,
sesquiterpenes, polysaccharides, peptidoglycans, fatty
acids, carbohydrates, and phenolic compounds (2). The
principal chemical constituents exhibiting purported pharmacological effects are triterpene saponins,
which are secondary metabolites of ginseng. Triterpene saponins are named ginsenosides Rx, in which the
“x” is designated following their mobility on thin-layer
chromatography plates, with polarity decreasing from
index “a” to “h”. Ginsenosides are glycosides containing an aglycone (protopanaxadiol or protopanaxatriol)
with a dammarane skeleton(7). Ginsenosides are polar
compounds, with the polarity a function of the number
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of monosaccharide residues present in the sugar chain.
There are 31 ginsenosides that have so far been isolated
and identified from the roots of white and red ginseng.
Ginsenosides can be categorized into three groups
based upon their aglycone groups: protopanaxadiol-type
ginsenosides, protopanaxatriol-type ginsenosides, and
oleanolic acid-type saponins (2). The types and quantities of ginsengosides are different among different
ginseng species, the age of the plant, and the part of the
plant extract. These variations account for the varying
purported therapeutic effects of ginseng products. The
more highly regarded ginseng products contain more
ginsenosides of the protopanaxtriol-type.
Most of dammarane ginsenosides in white ginseng
root are derivatives of 20(S)-protopanaxadiol and 20(S)protopanaxatriol (Table 1). The majority of the ginsenosides isolated in white ginseng are also present in red
ginseng. Some ginsenosides are characteristic saponins
for red ginseng(2). Panax ginseng and Panax quinquefolium are closely related chemically and taxonomically, with both containing ginseng saponin below 0.1
percent (8). The major difference between Panax ginseng
(Asian ginseng) and Panax quinquefolius (American and
Canada ginseng) is that Panax ginseng contains ginsenoside Rf and Panax quinquefolius does not (9).
The structures of the common ginsenosides are
shown in Figure 1 and the names (in abbreviation) of the
principal ginsenosides are listed in Table 1.

R3O
OH

R1O
R2

Figure 1. The 20(S)-protooanaxadiol and 20(S)-protopanaxatriol
components in ginseng root.

Table 1. The structures of the common ginsenosides.
I. 20(S)-protopanaxadiols
Ginsenoside

R1

R2

R3

Rb1

glc-glc

H

glc-glc

Rb2

glc-glc

H

glc-ara(p)

Rc

glc-glc

H

glc-ara(f)

Rd

glc-glc

H

glc

II. 20(S)-protopanaxatriols
Ginsenoside

R1

R2

R3

Re

H

-O-glc-rha

glc

Rf

H

-O-glc-glc

H

ENVIRONMENTAL OCCURRENCE

Rg1

H

-O-glc

glc

Rg2

H

-O-glc-rha

H

Panax ginseng species are produced in the Northern Hemisphere, from the eastern Himalayas through
China and Japan to North America. Panax quinquefolius
is found in eastern North America. Due to continuous
harvest for therapeutic usage and health care over thousands of years, the natural grown (wild) Panax ginseng
root has been exhausted in China for a long time. Naturally, wild ginseng has long been considered a threatened,
rare, or endangered species (2).
American ginseng has been exported to foreign countries, mainly Asia, since eighteenth century. For commercial needs, cultivated American ginseng was developed in
the twentieth century(10). American ginseng is now cultivated in China, Korea, Japan, and North America.

Rh1

H

-O-glc

H

DISPOSITION
After oral administration, ginsenosides are only
slightly decomposed by gastric juice (12), but are metabolized by intestinal bacteria; with protopanxadiols (Rb1)
probably being metabolized to 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) in rat and
human by intestinal anaerobes (12-16). Prevotella oris
strains of intestinal bacteria hydrolyzed protopanxadiols,

glc = glucose; ara(p) = arabinose in pyranose form; ara(f) =
arabanose in furanose form; rha = rhamnose. Sources: (2,11).

and the resulting metabolites are absorbed from the intestine (17). However, protopanxadiols (Rb1) are not well
absorbed in the intestine (18). After orally administering
protopanxadiols to mice, the level of 20-O-β-D- glucopyranosyl-20(S)-protopanaxadiol gradually increased in
the serum, reaching the peak at 8 hr. When 20-O-β-Dglucopyranosyl-20(S)-protopanaxadiol itself was orally
administered to the mice, its level reached the highest in
serum within 2 hr and decreased rapidly with time (13).
While ginsenoside Rg1, a 20(S)-protopanaxatriol,
(Table 1) had a short half-life of 27 min after i.v. administration to minipigs, protopanaxadiol ginsenoside Rb1 had
a much larger half-life (16 hr) in the B-phase (2). When
orally administered to the mice, ginsenoside Rg1 was
quickly absorbed and metabolized; with 30% of ginsenoside Rg1 being absorbed in one hr. These findings are
consistent with the results that mouse urine and feces
contained high levels of metabolites, including ginsenoside Rh1 and 25-OH-Rh1, while only a small amount of
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unchanged ginsenoside Rg1 was found (2).
Ginsenoside Rh2 underwent deglycosylation to
produce protopanaxadiol in B16 melanoma cells in vitro,
leding to growth inhibition of the B16 cells (19).

PURPORTED THERAPEUTIC EFFECTS
AND BIOLOGICAL EFFECTS
Much literatures, including original research papers,
reviews, and books, has reported the purported therapeutic
effects and biological effects of ginseng in details. In the
present review, these effects are described very briefly.
In China, Panax ginseng is regarded as “the allhealing man-herb”, and in the Far East it is considered as
something of a panacea. Ginseng is popularly used as an
aphrodisiac and a stimulant (20). It has been widely used
as geriatric tonic in Asia and recently in many Western
countries, purportedly for enhancing stamina and endurance both mentally and physically. The claimed therapeutic effects include anti-aging; beneficial effects on
diabetes, radiation sickness, ulcers, cardioprotection,
vasorelaxant, anemia, atherosclerosis, hypertension, and
edema; improving central nervous system with effects on
memory, learning and behavior; improving concentration
and depression, and stress reduction(4,11,21).
Protopanaxadiol, a metabolite of ginsenoside Rh2,
inhibited growth of B16 melanoma cells in vitro strongly
than Rh2 did(19). Administered orally to mice, ginsenosides Rb1, Rb2, Rg3 and Rc inhibited lung metastasis of
B16-BL6 and colon 26 cells by inhibition of angiogenesis(13, 22,23). Ginsenoside Rh2 was found to enhance antitumor activity and decrease cyclophosphamide-induced
genotoxicity(24).
Panax ginseng has been reported to inhibit a chemicalinduced carcinogen in rodents. Yun et al.(25) determined
that mice receiving prolonged administration of Korean
red ginseng inhibited or prevented carcinogenesis induced
by 7,12-dimethylbenz[a]anthracene (DMBA), urethane,
and aflatoxin B1. Korean red ginseng administered orally
inhibited liver cancer induced by diethylnitrosamine
(DEN) in Wistar rats(26). When red ginseng was given
together with urethane, there was a significant reduction in
urethane-induced lung adenoma(27). Gum et al.(28) determined that wild Panax ginseng C.A. Meyer efficaciously
protected against benzo[a]pyrene-induced hepatotoxicity through inhibition of metabolic regulation of CYP1A1
and the enhancement of electrophilic detoxification. Panax
ginseng extract, EFLA400, inhibited benzo[a]pyrene
induced lung adenoma in Swiss albino mice(29). Panax
ginseng was found to be capable of improving survival rate
and sperm quality to guinea pigs exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)(30).
Ginseng total saponins were found useful for the
prevention and therapy of the behavioral side effects induced
by psychotropic agents(31). Ginsenoside Rg(3), an active
ingredients in Panax ginseng, induced neuroprotection

against homocysteine-induced excitotoxicity in rat hippocampus. This protective effect is achieved via inhibition of
homocysteine-mediated NMDA receptor activation(32).
Orally administered ginsenosides are metabolized
to 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol
(compound K) by intestinal bacteria, which can protect
tert-butyl hydroperoxide induced liver injury in mice (16).
Lee et al.(33) found that Panax ginseng exhibited a therapeutic capacity to reduce pathological and genotoxical
damage in testes of rats exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin via reduction of CYP1A1 mRNA.
Ginsenosides (ginseng saponins) are the principal
components responsible for the majority of purported
pharmacological activities of ginseng(16). 20-O-beta-dglucopyranosyl-20(S)-protopanaxadiol is an intestinal
bacterial metabolite of protopanaxadiol-type saponins,
ginsenosides Rb1, Rb2, and Rc. It possesses antitumor
effects, including inhibition of invasion, metastasis and
angiogenesis, and induction of tumor cell apoptosis. This
metabolite exerts anti-inflammatory effects by inhibiting
TPA-induced COX-2 expression, expressing its antitumorpromoting effects on mouse skin carcinogenesis(16). 20-O(beta-D-glucopyranosyl)-20(S)-protopanaxadiol induced
apoptosis in human hepatoblastoma HepG2 cells(34). The
very low toxicity in normal hepatocytes and high activity
in hepatoblastoma HepG2 cells suggest that 20-O-(betaD-glucopyranosyl)-20(S)-protopanaxadiol is a potential chemopreventive agent(34). Ginseng extract exerted
protective effects against apoptotic cell death induced
by 2,2’,5,5’-tetrachlorobiphenyl in neuronal SK-N-MC
cells(35).
Ginsenosides Rb1 and Rg1 are effective therapeutic agents for neurological disorders, including spinal
cord injuries (36). Panax ginseng extract standardized
with ginsenoside Rg3 protected effectively against acrylamide-induced neurotoxicity in rats (37).
Ginseng has been reported to have a positive effect
on the immune system, stimulating the phagocytic function of the reticoloendothelial system leading to an increase
in serum-specific antibodies and IgG content and also an
increase in the relative percentages of protective B-lymphocytes(2). Ginsenosides were reported to effectively reduce
cisplatin-induced nephrotoxicity(7). Ginsenosides induced
differentiation of F9 teratocarcinoma stem cells and loss of
tumorigenicity(38). Bao et al.(39) determined that ginsenosides Rg3(S) and Rg5/Rk1 significantly reversed the
memory dysfunction induced by ethanol or scopolamine,
and exhibited neuroprotective effects. Ginsenoside Rb(1)
possessed anti-inflammatory properties(40).
Van Kampen et al.(41) determined that oral administration of ginseng extract G115 exerted neuroprotective
actions in two rodent models of Parkinson’s disease.
Administration of ginsenoside-Rb2 to streptozotocin-induced diabetic rats reduced the level of blood
glucose, producing an improvement in hyperglycemia.
Rb2-treated animals also showed a significant decrease
in activity of glucose-6-phosphatase, a significant rise of
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glucokinase activity in the liver, and a moderate increase
in glycogen content (42). Ginseng seems to have a direct
and an indirect action on oxidative damages. Evidence
from in vitro studies showed that the pharmacological
actions of ginseng are due to its antioxidant/nitric oxide
(NO) stimulating properties (43,44).
Ginseng exhibits antioxidant/nitric oxide effects(43,44).
Ginseng activates the transcription of the superoxide
dismutase gene(45). The cardiovascular effects of ginseng
root and individual ginsenosides have been studied. Many
reports describe vasodilator actions, in some cases followed
by vasoconstriction and increase in blood pressure(11).

GINSENG TOXICITY
I. Human Data
There are no epidemiological studies or case reports
that are associated with exposure to ginseng and cancer
risks in humans. When toxicity of ginseng was reported, the form, quantity, and quality of ginseng used were
not specified. The diets, the use of other drugs, and the
stress condition of the patients were also not known.
Thus, toxicity of ginseng in humans is difficult to evaluate. Characteristic signs and symptoms of overexposure
to ginseng have been termed ginseng abuse syndrome.
Siegel(46) studied ginseng abuse syndrome examining
133 persons who took ginseng regularly for at least one
month. Most subjects experienced central nerve system
(CNS) excitation and arousal. Fourteen subjects who took
Panax ginseng roots suffered from hypertension, nervousness, sleeplessness, skin eruptions, and morning diarrhea,
among which, five had edema and ten became euphoric,
restless, agitated, and insomniac. Ten taking high doses
(15 g) felt depersonalization and confusion. The average
daily dose of ginseng roots was 3 g for persons experiencing ginseng abuse syndrome. Ginseng abuse syndrome
appeared periodically in the first 12 months of ginseng use
but the syndrome was rarely reported in follow up examinations at 18 and 24 months(46).
A 28-year old woman who ingested a large quantity of ethanol-extracted ginseng developed a severe
headache, nausea and vomiting, and chest tightness. It
has also been reported that ginseng exerted estrogenic
effects in women, causing vaginal bleeding in postmenopausal women(4). Chronic administration of ginseng has
been associated with the occurrence of vaginal bleeding,
mastalgia, mental status changes and Stevens-Johnson
syndrome (20). A 44-year old woman taking ginsengcotaining face cream developed an episode of postmenopausal bleeding(47). A 39-year old man who long term
ingested ginseng developed hypertension, dizziness,
and inability to concentrate. He stopped taking ginseng,
became normotensive within five days, and after three
months his symptoms resolved(48).
The U.S. Food and Drug Administration’s Special

Nutritionals Adverse Event Monitoring System reported 114 illnesses or injuries associated with the use of
ginseng-containing special nutritional products and
dietary supplements on May 14, 1998. Thirteen deaths
were reported. For 17 products that apparently contained
only ginseng as an active ingredient, the following
effects were reported: tonic-clonic seizure and two mild
strokes; pruritus and jaundice; vomiting, nausea, diarrhea, and perspiration; dermatomyositis; coma; stomach
pains; rash and searing pain; heart palpitations, sweating,
and “felt like speeding”; scratched esophagus; nausea,
vomiting, dizziness, and blurred vision; atrial fibrillation;
and thrombocytopenia, necrotic tissue in bone marrow,
followed by death; chest pain, feeling of constriction,
heart pounding, anxious, and pale; headache, nausea, and
vomiting; and abnormal uterine bleeding (49).
Hypertensive individuals who chronically take ginseng
may have problems with control of blood pressure(50).
II. Herb-Drug Interaction
Herbal medicines, including herbal supplements, are
often administered in combination with therapeutic drugs,
both of which require metabolizing enzymes for metabolism, and very likely raise the potential of herb-drug interactions, causing an adverse nature (51-56). Ginseng is one of
the most popular geriatric dietary supplements. Gurley et
al.(55) studied the effects of Panax ginseng on cytochrome
P450 phenotypes in the elderly and determined that Panax
ginseng significantly inhibited CYP2D6, but the magnitude of the effect did not appear to be clinically relevant.
Hu et al.(53) stated that upon herb-drug interactions,
Panax ginseng reduced the blood concentrations of alcohol and warfarin and induced mania when used concomitantly with phenelzine.
III. Animal Data
(I) Acute Studies
The Registry of Toxic Effects of Chemical Substances (RTECS) listed several acute toxicity values for various ginseng products, which are shown in Table 2.
The work by(59,60) demonstrated that ginsenoside aglycones 20(S)-protopanaxadiol, 20(S)-protopanaxatriol, and

Table 2. LD50 (mg/kg) values for ginseng(57,58)
Compound

Species

Route

LD50 (mg/kg)

Rat

Oral

750

Mouse

Oral

200

Mouse

IP

54

Ginseng root extract

Mouse

IP

545

Ginsenoside No. 3

Mouse

IP

910

Ginseng, saponin extract

Mouse

IP

637

Panax ginseng
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ginsenoside Rh2 induced cytotoxicity in intestinal Caco-2
cells. Ginsenoside Rd from Panax notoginseng was found
cytotoxic towards HeLa cancer cells and induces apoptosis
through down-regulating Bcl-2 expression, up-regulating
Bax expression, lowering the mitochondrial transmembrane potential, and activating the caspase-3 pathway(61).
(II) Subacute/Subchronic Studies
Hess et al.(62) reported that male and female SpragueDawley rats fed a diet containing G115 with 15 mg/kg/
d for 13 weeks did not develop histopatholgical changes. Beagle dogs fed diets containing 0, 1.5, 5, or 15 mg
ginseng extract G115 per kg of body weight per day for
90 days also exhibited no toxicity was observed. Gross
and microscopic examinations of major organs revealed
no morphological or pathological effects. The highest
dose, 15 mg/kg, is approximately twice the recommended
dose for humans (63). No toxic effects were found in rats
following ingestion of ginseng extract at daily dose levels
of 105-210 mg/kg for 25 weeks (64).
(III) Chronic/Carcinogenicity Studies
In a chronic study in LACa mice, there were three
groups with 90 animals per group; one group consumed
ginseng extract from 8 weeks of age throughout life;
the second group received ginseng from 52 weeks
onward; and the third group served as untreated controls.
Ginseng extract was administered in drinking water at a
dose of 8 mg/kg/day, corresponding to 40 mg of whole
root/kg/day(65). This study was not designed to examine carcinogenicity; therefore, histopathology was not
performed and no attempt to define maximum tolerated dose was made. No significant differences in mean
weights or survival were observed in mice consuming
Panax ginseng, although increased behavioral responses
to mild stress were observed. Ginseng administration
did not alter the lifespan of the mice but their behavioral response to stress was exaggerated (65). However, the
dose level used was considered low.
(IV) Genotoxicity Studies
Chang et al.(66) reported that both the water extract
of Panax quinquefolius roots and the n-butanol extract
of ginsenosides were not mutagenic in Salmonella
typhimurium strain TM677 with or without metabolic
activation. When assayed in Bacillus subtilis strains
H17Rec+ and M45Rec- and in Salmonella typhimurium
strains TA98 and TA100 with or without PCB-induced
rat liver S-9, Panax japonicum and Panax ginseng were
not mutagenic (67). However, the extract of Panax ginseng
root exhibited inhibitory effects on DNA synthesis,
measured by thymidine incorporation into V79 Chinese
hamster lung cells (68).
While ginsenoside Rg1, an active component of

ginseng, stimulated mitosis in the bulb and seedling root
tip cells of Allium cepat, ginsenoside Rb1 inhibited mitosis in the cells (69).
The U.S. National Toxicology Program (NTP) is
conducting a 2-year carcinogenicity study of Panax
ginseng (Asian ginseng). A detailed description of this
study is given in a following section.
(V) Reproductive Toxicity Studies
Chan et al.(70) studied embryotoxicity of ginsenoside
Rc and Re in rat whole embryo culture and found that
ginsenoside Re resulted in a significant lower median
morphological score, a fewer number of somites, and a
smaller yolk sac diameter and crown-rump length. In
contrat, there was no significant embryotoxic effect
by exposure to ginsenoside Rc. Liu et al.(71) employed
whole embryo culture to explore the developmental toxicity of ginsenoside Rb1on mouse embryos. The results
suggest that GRb1 exhibited teratogenic effect during the
mouse organogenetic period. Ginsenoside GRg1 exerted
embryotoxicity during both rat and mouse organogenetic
period, with the effect higher in rats than mice (72).
(VI) Effect on Cytochrome P450 Enzymes and Herb-Drug
Interactions
Lee et al.(73) studied the in vivo effects of Panax
ginseng extracts on the cytochrome P450 enzymes in the
liver of guinea pig treated with 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD). It was found that Panax ginseng extracts
may act as an inhibitor of CYP1A, but not of CYP2B.

REGULATORY STATUS
In the United, no standards or guidelines have been
set by NIOSH or OSHA for occupational exposure to
or workplace maximum allowable levels of ginseng.
Ginseng is not on the American Conference of Governmental Industrial Hygienists (ACGIH) list of compounds
for which recommendations for a Threshold Limit Value
(TLV) or Biological Exposure Index (BEI) are made.
International trade in American ginseng is regulated
under the provisions of the Convention on International
Trade in Endangered Species (CITES), which regulates
trade through permit requirements for imports, exports,
and re-exports of listed species. Harvest and commerce
are regulated and restricted both jointly and separately by
state agencies, the US Fish and Wildlife Service, and the
United States Department of Agriculture (74).
Since 1994, dietary supplements have been regulated under the Dietary Supplement Health and Education
Act (DSHEA). The DSHEA requires no proof of safety
for dietary supplements on the market prior to October
15, 1994. Labeling requirements for such supplements
allow warnings and dosage recommendations as well as
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substantiated “structure or function” claims. All claims
must prominently note that they have not been evaluated
by the FDA, and they must bear the statement “This product is not intended to diagnose, treat, cure, or prevent any
disease”(75).
Ginseng is more closely regulated in Europe. The
German government’s Commission E requests Panax
ginseng products containing at least 1.5 percent ginsenosides, calculated as ginsenoside Rg1. The products
must also be labeled for use as a tonic for invigoration
and fortification(76).

TOXICOLOGY EVALUATION BY THE
NATIONAL TOXICOLOGY PROGRAM (NTP)
The NTP is the U.S. government program established to evaluate substances for health-related effects,
generally using rodent models for study and protocols
specifically designed to characterize fully the toxic
potential and address specific deficiencies in the toxicology database for the chemical. The studies generally
provide toxicological information on effects on hematological and clinical chemistry, immunotoxicity, neurotoxicity, reproductive toxicity, genotoxicity, and carcinogenicity of the chemical. In addition, the studies also
attempt to identify the active metabolite and its mode of
action. The data generated are used in the hazard identification step of the risk assessment process. The NTP
study data are used by the U.S. Federal and State Regulatory Agencies in considering the need for regulation of
specific chemicals to protect human health.
Ginseng was presented to the NIH Chemical Study
Working Group as part of a review of botanicals used as
dietary supplements. Worldwide, ginseng production is a
$3 billion industry. Asia is the largest market. Ginseng
is also a popular herbal remedy in the United States,
with five to six million persons using it even before the
recent boom in the herbal supplement industry. Although
ginseng root is commonly used, a standardized ginseng
extract, Ginsana (G115 ginseng), with annual sales of
over $40 million, is the most popular encapsulated form.
Numerous reports of adverse effects from products
containing ginseng have been filed with the U.S. Food
and Drug Administration (FDA). The literature also
documents “ginseng abuse syndrome” among regular
users. The chronic effects of ginseng are not well characterized; studies of some components suggest anticarcinogenic activity. The rationale for nomination of ginseng
for study was because of 1) Significant human exposure.
Ginseng is one of the most popular herbal supplements in
the U.S. market; Ginsana (G115 ginseng) is a standardized extract that controls half of this market, 2) Little
information on toxicity is available. The active ingredients may be dammaranes; RB1 ginsenoside is a commercially available dammarane found in ginseng, and 3) The
possibility that these compounds may have anticarcino-

genic activity should also be considered.
In general, the effects of ginseng reported in the literature are mostly derived from observation of the use of
genseng extracts, not individual ginsenosides. Consumers
also use extracts sold on the market. Since Ginsana (G115
ginseng) is a standardized product containing 4% extract
and has more than 50% of the market, the use of Ginsana (G115 ginseng) in the NTP studies was recommended.
The study of ginseng by the NTP is on-going. The protocol outline of the NTP pre-chronic and chronic toxicity
evaluation of ginseng will be described in detail after the
following Perspectives section.

PERSPECTIVES
Since the U.S. Congress passed the Dietary Supplement Health and Education Act (DSHEA) in 1994, herbal
products represent the fastest growing segment of the
VMH (Vitamin, Mineral supplements, and Herbal products) industry. According to DSHEA, a dietary supplement is considered unsafe only if it presents a significant
or unreasonable risk of illness or injury under conditions of use recommended or suggested in labeling, or if
no conditions of use are suggested or recommended in
the labeling, under ordinary conditions of use. Thus, to
ensure consumer health protection, the quality and safety
of herbal plants and herbal dietary supplements have to
be determined. To date, safety of herbal plants and herbal
dietary supplements is a major concern but the subject
has been focused primarily on external contaminations
such as microbial toxins and environmental pollutants of
metals and pesticide residues. Other safety issues, such
as undesirable side-effects and product stability are not
addressed adequately, and toxicological data on the identification of genotoxic and tumorigenic ingredients in
many herbal plants and herbal dietary supplements that
are commercially available in the market are also lacking.
As exemplified with the study of Panax ginseng in this
review, currently, the United States National Toxicology
Program (NTP) is conducting long term research projects
to determine the toxicity and tumorigenicity of a number
of dietary supplements and active ingredients nominated
by the U.S. FDA and U.S. National Institutes of Health.
An organized effort with international participation on the
subject should be actively pursued to ensure the safety of
commercial herbal plants and their derived products, such
as herbal dietary supplements.

PROTOCOL OUTLINE OF THE NTP
PRECHRONIC AND CHRONIC
TOXICITY EVALUATION OF GINSENG
Title: Chronic gavage toxicity/carcinogenicity study of
ginseng in Fischer 344 rats (Project No. G004512-O)
CAS Number: 50647-08-0
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Objective: To characterize the toxicity of ginseng in Fischer
344 rats and B6C3F1 mice.
A. 14-Day Repeated Dose Toxicity Study
Purpose: This study shall provide a basis for determining
doses for the 13-week subchronic toxicity study.

B. 13-Week (90-day) Subchronic Toxicity Study
Purpose: In addition to obtaining toxicological data,
this study will also help to determine the doses for each
strain and species to be used in the chronic two year
toxicity study.

Treatment:
The product G115 extract (Ginsana), which was used
in the present study, was purchased from PlusPharma,
Inc. (Vista, CA). It is an extract of Panax ginseng and
contains 4% ginsenosides or triterpene saponins.
After a ten to fourteen day quarantine period, animals
shall be assigned at random to treatment and control
groups. At each of five concentrations (0.125, 0.25, 0.5,
1.0, 2.0 g/kg) plus a vehicle control group, five animals per
sex per species shall receive the subject chemical in methylcellulose via gavage. The schedule will be twelve dose
days, not including weekends or holidays with at least two
consecutive dose days before the terminal sacrifice day.
Dose days missed due to holidays are to be made up before
sacrifice. All mice shall be housed individually and rats
shall be housed five per cage.

Treatment:
After a ten to fourteen day quarantine period,
animals shall be assigned at random to treatment and
control groups. At each of five concentrations plus a
vehicle control group, ten animals per sex per species
shall receive the subject chemical in methylcellulose via
gavage. The schedule shall be five times per week, weekdays only and exclusive of holidays, with all animals
remaining on the treatment regimen until the day (within
24 hr) of sacrifice. All mice shall be housed individually
and rats shall be housed five per cage.
Test Groups

Animals

Sexes

Treatment

Animals

Sexes

Species

Dose Levels

Total

Treatment

5

×

2

×

2

×

5

=

100

×

2

×

2

×

1

=

20

Untreated/vehicle
Controls
Total

5

120

Observations:
Animals shall be weighed individually on day one
on test, after seven days, and at sacrifice. The animals
shall be observed two times daily, once in the early
morning and once in the late afternoon at least 6 hr apart
(before 10:00 AM and after 2:00 PM), including holidays
and weekends, for moribundity and death. Observations
shall be made twice daily for clinical signs of pharmacologic and toxicologic effects of the chemical. Clinical
signs shall be recorded daily by animal number and made
a part of the study report. Organ weights shall be determined for all animals surviving until the end of the study.
The organs to be weighed are: liver, thymus, right kidney,
right testicle, heart, and lungs. Organs shall be weighed
to the nearest 10 mg except for testis and thymus which
shall be weighed to the nearest 1.0 mg.
Necropsy and Histopathologic Evaluation:
A complete necropsy shall be performed on all treated
and control animals that either die or are sacrificed, and all
tissues specified in the SOW (Section IV.B.) shall be saved
in formalin. This shall be done for all animals in all groups.
Histopathologic evaluation shall be done on 4 tissues
(brain, liver, lung, kidney) and those organs/tissues
showing gross evidence of lesions. The male and female
reproductive organs shall also be evaluated if abnormal.

Dose Levels

Total

10

×

2

×

2

×

5

=

200

×

2

×

2

×

1

=

40

2

×

1

×

5

=

100

×

1

×

1

=

20

Untreated/vehicle
Controls

Test Groups

Species

10

*Special rats for clinical
lab studies

10

×

*Special controls for clinical
lab studies
Total

10

×

2

360

* Special rats are to be treated for 21 ± 2 days for use in
conducting clinical lab studies at days 4 ± 1 and 21 ± 2,
after which they are to be sacrificed by exsanguination (see
special studies for serum hormone determinations) and no
tissues saved. Body weights and clinical observations will
not be measured for the additional rats treated for clinical lab studies. Clinical lab studies and serum hormone
determinations shall also be conducted on core study rats
at terminal sacrifice. Hematology measurements shall be
made on mice at terminal sacrifice.
Observations:
Animals shall be weighed individually on day one
on test, after seven days and at weekly periods thereafter. The animals shall be observed twice daily, once in
the early morning and once in the late afternoon, at least
6 hr apart (before 10:00 AM and after 2:00 PM), including holidays and weekends for signs of moribundity and
death. Signs of toxicity noticed during these routine
checks shall be recorded. Formal clinical observations
shall be performed and recorded weekly. An animal
survival report shall be submitted on the 1st and 15th day
of each month during the course of the study.
Organ weights shall be determined from all animals
surviving until the end of the study. Those organs to be
weighed are: Liver, thymus, right kidney, right testis,
heart, and lungs. Organs shall be weighed to the near-
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est 10.0 mg except for testis and thymus which shall be
weighed to the nearest 1.0 mg.
Necropsy and Histopathologic Evaluation:
A complete necropsy shall be performed on all treated and control animals that either die or are sacrificed,
and all tissues as listed in Section IV.B.of the SOW shall
be saved in formalin. All tissues required for complete
histopathology as listed in this protocol shall then be
trimmed, embedded, sectioned and stained with hematoxylin and eosin for possible histopathologic evaluation.
This shall be done for all animals in all groups.
A complete histopathologic evaluation inclusive
of gross lesions shall be done on all control animals, all
animals in the highest dose group with at least 60% survivors at the time of sacrifice, plus all animals in higher
dose groups inclusive of early deaths and survivors.
Chemical-related lesions (target organs) shall be identified, and these organs plus gross lesions shall be examined in all lower doses. The pathologist shall evaluate
only those tissues designated as target tissues and gross
lesions in lower dose levels. However, a complete histopathologic evaluation shall be performed on all natural
death/moribund sacrifice animals in lower dose groups.

LIST OF TISSUES FOR COMPLETE
HISTOPATHOLOGIC EVALUATION FOR
THE 13-WEEK (SUBCHRONIC) STUDIES
Adrenal glands
Brain (3 sections including frontal cortex and basal ganglia,
parietal cortex and thalamus, and cerebellum and
pons)
Clitoral glands
Esophagus
Eyes (if grossly abnormal)
Femur, including diaphysis with marrow cavity and epiphysis (femoral condyle with epiphyseal cartilage plate,
articular cartilage and articular surface)
Gallbladder (mouse)
Gross lesions
Heart and aorta
Intestine, large (cecum, colon, rectum)
Intestine, small (duodenum, jejunum, ileum)
Kidneys
Liver (2 sections including left lateral lobe and median lobe)
Lungs and mainstem bronchi
Lymph nodes - mandibular and mesenteric
Mammary gland with adjacent skin
Muscle, thigh (if neuromuscular signs were present)
Nasal cavity and nasal turbinates (3 sections)
Ovaries
Pancreas
Parathyroid glands
Pituitary gland
Preputial glands

Prostate
Salivary glands
Seminal vesicle
Spinal cord and sciatic nerve (if neurologic signs were present)
Spleen
Stomach (forestomach and glandular)
Testes with epididymus
Thymus
Thyroid glands
Tissue masses and regional lymph nodes
Trachea
Urinary bladder
Uterus
Specific Toxicologic Parameters to be Evaluated in the
13-Week Subchronic Study
(1) Clinical Laboratory Studies
Additional rats shall be treated, both sexes, all dose
groups, for collections at days 4 ± 1 and 21 ± 2. Blood
shall be collected from the retroorbital sinus under CO2
anesthesia at days 4 ± 1 & 21 ± 2 from the special study
rats and these animals shall be sacrificed after the collection for day 21. The core study rats shall be bled for the
terminal collection. Core study mice shall be bled at
terminal sacrifice for hematology determinations.
All male and female animals shall be treated the same
number of days before collection of samples and all animals
of a sex shall be bled on the same day. The period between
the start of the study and the collection of the first sample at
day 4 ± 1 shall be continuous, not interrupted by a weekend
without treatment.
(i)

Hematology Erythrocyte count
Mean corpuscular volume
Hemoglobin
Packed cell volume
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin concentration
Erythrocyte morphologic assessment
Leukocyte count
Leukocyte differential
Reticulocyte count
Platelet count and morphologic assessment

(ii) Clinical chemistry to include Sorbitol dehydrogenase (SDH)
Alkaline Phosphatase (ALP)
Creatine Kinase (CK)
Creatinine
Total Protein
Albumin
Urea Nitrogen (BUN)
Total Bile Acids
Alanine Aminotransferase (ALT)
Glucose
Cholesterol
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Triglyceride
(iii)	Serum corticosterone (blood to be drawn early in the
morning)
The results of all automated measurements for clinical pathology (unaudited data) shall be reported to the
NTP within seven calendar days after sample collection,
for the early time points and within 21 days for measurements conducted at terminal sacrifice.
(2) Blood Smears for Micronuclei
Two unstained blood smears shall be prepared from
mice at termination of the 13-week study for use by the
NTP in micronuclei determinations (procedures are
described in the SOW).
(3) SMVCE
(4) Special Studies
(i)	Optional neuroreproductive, and developmental
toxicity studies
(ii)	Optional special staining for brain tissues (Note:
brain tissue shall be removed and fixed immediately
after sacrifice before examining and removing other
organs)
C. Chronic Toxicity/Carcinogenicity Study
Objective: To determine the chronic toxicity and carcinogenicity of ginseng administered by govage to Fischer 344 rats
and B6C3F1 mice.
Treatment:
After a ten to fourteen day quarantine period, rats
and mice shall be assigned at random to treatment and
control groups. Female rats and female mice shall be
housed in groups of five animals per cage, and male rats
shall be housed in groups of three per cage. Male mice
shall be individually housed.
Rats and mice shall receive the test chemical in
methylcellulose for 104 weeks via gavage at 3 doses plus
controls. Treatment shall be five days a week, excluding
weekends and holidays.
Animals

Sexes

Species

Dose Levels

Total

Treatment

50 ×

2

×

2

×

3

= 600

Controls

50 ×

2

×

2

×

1

= 200

Sentinel Animals

15 ×

2

×

2			

Total

=

60
860

Observations:
Individual animal body weight for test and control
group animals shall be recorded on day one on test, and
at 4 week intervals thereafter. If life threatening tumors
develop, a significant number of deaths occur, or a significant effect on body weight is observed, the weighing

frequency may be increased to every two weeks upon
approval by the NTP Project Officer. It is estimated that
animals will be weighed every two weeks for the final
thirteen weeks of the chronic study.
Animals shall be observed two times daily, once in
the early morning and once in the late afternoon at least
six hours apart (before 10:00 am and after 2:00 pm including holidays and weekends) for morbidity and mortality.
Each animal shall be formally examined for clinical
signs of toxicity at four week intervals and these observations shall be recorded. Signs of toxicity detected at
times other than the formal four week observations shall
be noted and recorded.
Necropsy and Pathology:
Necropsy Examination: All animals from all treated
and control groups which die or are sacrificed during and
at the end of the experiment receive a complete necropsy examination. All tissues from all animals shall be
preserved in formalin as specified in the NTP Specifications. All tissues required for complete histopathologic
examination shall be trimmed, embedded, sectioned and
stained with hematoxylin and eosin for histopathologic
examination.
Histopathology: All animals which die (or are sacrificed in
a moribund condition) are subjected to a complete necropsy
and slides of all tissues required for complete histopathologic evaluation shall be prepared and evaluated. PEIS Individual Animal Necropsy Records for these animals shall be
submitted to the NTP Project Officer on the 1st and 15th day
of each month. As a routine, the complete histopathologic
evaluation of these tissues will be conducted at the end of
the study. However, if histopathology evaluation on early
death/sac animals is requested earlier by the NTP, it shall be
completed within 30 days of notification.
Animals that are exposed for 104 weeks shall be
sacrificed without a recovery period and shall be given
a complete necropsy and histopathologic evaluation. All
tissues required for complete histopathology shall be
evaluated in all dose groups and controls.

LIST OF TISSUES FOR COMPLETE
HISTOPATHOLOGIC EVALUATION
IN CHRONIC STUDIES
Adrenal glands
Brain (3 sections including frontal cortex and basal ganglia,
parietal cortex and thalamus, and cerebellum and pons)
Clitoral glands
Esophagus
Eyes (if grossly abnormal)
Femur, including diaphysis with marrow cavity and epiphysis (femoral condyle with epiphyseal cartilage plate,
articular cartilage and articular surface)
Gallbladder (mouse)
Gross lesions
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Heart and aorta
Intestine, large (cecum, colon, rectum)
Intestine, small (duodenum, jejunum, ileum)
Kidneys
Liver (2 sections including left lateral lobe and median lobe)
Lungs and mainstem bronchi
Lymph nodes - mandibular and mesenteric
- inguinal, gluteal, internal iliac (chronic
studies only, if lesion observed, not merely
discoloration)
Mammary gland with adjacent skin
Muscle, thigh (only if neuromuscular signs were present)
Nasal cavity and nasal turbinates (3 sections)
Ovaries
Pancreas
Parathyroid glands
Pituitary gland
Preputial glands
Prostate
Salivary glands
Seminal vesicle
Spinal cord and sciatic nerve (if neurologic signs were present)
Spleen
Stomach (forestomach and glandular)
Testes with epididymus
Thymus
Thyroid glands
Tissue masses and regional lymph nodes
Trachea
Urinary bladder
Uterus
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